NCT00833963View on ClinicalTrials.gov

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

January 14, 2009

Primary Completion Date

April 13, 2017

Study Completion Date

April 13, 2017

Conditions
Breast CancerPregnancy
Interventions
DRUG

Trastuzumab

Participants will receive trastuzumab as determined by their treating physicians' standards of care.

DRUG

Pertuzumab

Participants will receive pertuzumab as determined by their treating physicians' standards of care.

DRUG

Ado-Trastuzumab Emtansine

Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.

Trial Locations (1)

28405

Kendle International, Inc, Wilmington

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY